Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Stephen Simpson, CFA, is a freelance financial writer and investor.
I have worked for both sell-side and buy-side firms (equities and fixed income), with the largest percentage of my working time spent in med-tech. At this point I am now effectively in a "working retirement".
As I am helping my partner of 20+ years in her battle against stage IV cancer, I don't really have the time to be very involved with comments. Likewise, I may not be able to update a particular story/situation/investment idea in an especially timely fashion.
I write because I find that the process helps me take better notes, be more disciplined about modeling, and come up with a more coherent investment view for my portfolio management needs. If I'm writing about a stock, it's generally because I'm interested in it as an investment prospect or I think there's an interesting story to tell.
I don't share my models, so please don't ask.
More of my writings can be found at my blog Kratisto Investing (kratistoinvesting.blogspot.com), or Twitter (@Kratisto_Invest).
Aaron F. Barkoff is a patent attorney at McAndrews, Held & Malloy, Ltd., a law firm in Chicago. Aaron specializes in representing pharmaceutical and biotechnology companies. He is especially interested in issues that overlap between patent law and food & drug law, and he authors a weblog, Orange Book Blog, that reports on those issues.
I hold degrees in Biochemistry and Business from NC State University in the heart of RTP, NC. My work experience has been in Microbiology and Pharmacy. I have experience with FDA decisions and Clinical Trials. I seek bargains and low prices, and follow Warren Buffett's principles. At the same time I am my own investor and don't always follow the same rules as everyone else. I am not opposed to Shorting Stocks and you should learn the importance of a short in the trading BioPharma Market.
See Seeking Alpha's policy on anonymous authors: http://seekingalpha.com/article/69847-seeking-alpha-policy-on-anonymous-authorship
Leonard is an editor of BioTuesdays.com. Before joining the blog, Leonard amassed 36 years of experience as a financial journalist, editor and manager with The Wall Street Journal and Dow Jones News Service, and The Globe and Mail’s Report on Business, where he pioneered the development and launch of the newspaper’s Money & Markets section in the early 1990s. Most recently, he was Canada’s leading biotechnology and healthcare writer, as well as the author of a highly popular stock market blog on globeandmail.com.
Chris Holt is the Managing Editor of AllAboutAlpha.com, a popular industry website/blog covering research and trends in alternative investments. In 2008, Pensions & Investments magazine ranked AllAboutAlpha.com as one of the world’s 10 best financial blogs, alongside the blogs of the Wall Street Journal and Financial Times. He has written over 1,000 articles on the hedge fund sector, with an emphasis on industry trends, academic research, surveys, and practitioner research. In his role with AllAboutAlpha.com, Chris is also a regular chair and moderator at hedge fund industry events around the world, including the semi-annual “Global Absolute Return Congress,” the world’s leading alternative investment conference for pensions and foundations.
Chris is also head of industry relations in the Americas for the Chartered Alternative Investment Analyst (CAIA) Association. The CAIA Association is a non-profit global association of alternative investment professionals and is the sponsor of the CAIA designation. Based in Amherst, MA, the CAIA Association has offices in London, Singapore and Toronto and has a dozen chapters in the world’s largest financial centers.
Prior to this, Chris was head of marketing for one of Canada’s largest hedge fund companies, and was a management consultant with several firms including Ernst & Young. Separately, he also consulted to the Annual Meeting of the Swiss-based World Economic Forum for 10 years. He is currently a member of the Editorial Board of the Journal of Alternative Investments, has an MBA from Duke University and is a CAIA Charter holder.
Visit his site: All About Alpha (http://www.allaboutalpha.com/blog/)
Editor and Publisher ... Henry enters his thirteen (13) year at RegMed Investors which aggregates, curates and creates bottom-line content of regenerative medicine - stem, gene and cell therapy news providing a "vetted" selection of relevant and high-impact synthesis.
He was VP - Strategic Planning and Communication at Curis (2001-2002), HQCM focusing on healthcare investments (NYSE:HQH/HQL) from (1985-2001)and founded LifeScience Economics, a healthcare research and analytics firm with offices in Boston, MA and Palo Alto, CA. Past experiences include Thermo Scientific, SWEC following 5 years at the FBI. A former military officer, Henry has been an adjunct professor at Boston University and Golden Gate University where he taught courses in venture capital, corporate finance and strategic development in the universities' graduate business schools.
Peter Navarro is a business professor at the University of California-Irvine. He is the author of the path-breaking management books The Well-Timed Strategy, and The Coming China Wars, and the bestselling investment book If It's Raining in Brazil, Buy Starbucks. His latest book is Crouching Tiger: What China's Militarism Means for the World.
Navarro's articles have appeared in a wide range of publications, from Business Week, Los Angeles Times, New York Times, and the Wall Street Journal to Harvard Business Review, the Sloan Management Review, and the Journal of Business. Professor Navarro is a widely-sought after and gifted public speaker. He has appeared frequently on Bloomberg TV and radio, CNN, CNBC, and NPR.
John received his PhD in chemistry in the research group of Nobel Laureate Donald Cram in 1987 and his MBA from the Anderson School of Management at UCLA in 2009. His research career spans 16 years performing drug discovery research in metabolic diseases, cancer, HIV infection, antibacterials, and Alzheimer's disease. In 2011 John joined Sagient Research Systems as a Biotechnology Analyst. In 2013 he joined Zack's Small Cap Research as an Analyst.
On Twitter: @johntuckerphd
As John is neither licensed nor qualified to act as an investment advisor, his articles are written for discussion purposes only and should not be construed as investment advice. He makes a reasonable effort to avoid misstatements of fact, but advises all investors to consult primary sources prior to making an investment.
M.E. Garza is one of the founders of the biotech and healthcare sector news portal BioMedReports.com. He believes in getting the news from credible sources on the street and often reaches out to CEOs and newsmakers directly for interviews and discussions about their companies. Since he began publishing in 2008, Garza has built a reputation as a writer and reporter who can move markets. His track record for accurately reporting rumors and alerting readers about developments in the biotech/healthcare sector is unmatched during that time.
Sheff can be followed at twitter.com/SheffStation. He is an investor & trader of big board, small cap, and biotech stocks. He uses fundamental analysis and extensive DD (due diligence) to trade. Over the years, he has learned a great deal about how the FDA works and what they look for when considering a drug for approval. His success record in stock picking and many yrs in the biotech & pharmaceutical industry has helped him in his analysis of biotech & pharma stocks. His goal is to find undervalued companies and help the individual investor by discussing clinical data that could be relevant in how the FDA will make a decision for a drug or clinical data.
Do your own due diligence and never buy a stock based on what Sheff discusses or says.
Sheff is is not a licensed broker or financial advisor of any kind nor is he qualified to act as an investment advisor. His articles are written for discussion purposes only. None of the information written about by Sheff is to be construed as financial or investment advice. The information shared is not to be construed as an offer to buy or sell any security. Sheff works diligently to avoid misstatements of fact, but advises all investors to consult a licensed profession prior to making an investment in any stock he discusses. The information on this site is gathered from sources available to the public
Sheff's hobbies are reading, family, and helping people. I enjoy the work I do as a Chemo Specialist in many cancer centers and the volunteer work as a member with a Cancer Organization where I raise money for awareness & other programs vital for children with different forms of cancer.
Mike Havrilla is a pharmacist, biotech stock trader and writer with experience that includes licensed pharmacist since January 2004, online trading since August 1997 and writing for investors since April 2007. Mike holds Doctor of Pharmacy and Bachelor of Science (Biology) degrees from the University of Pittsburgh and worked in the pharmaceutical industry for Wyeth prior to pharmacy school. He is also an avid runner and has completed over 20 marathons with a personal best time under three hours for the 26.2 mile race. Mike merged his former publishing business with BioRunUp.com / Mark Messier in October 2010, creating a new online biotech stock research and trading subscription service.